1 in 3

 

...individuals will be affected by Alzheimer's disease by the age of 80.

 

Alzheimer's Drug Discovery Foundation

 

 
RECENT NEWS

 

November 6 - 8, 2011:  Dr. Greg Hook, Co-Founder, Vice President and Corporate Counsel at American Life Science Pharmaceuticals, ALSP Inc., presents the lead compound at Partnering For Cures in New York, NY. The compound, which represents a new class of Alzheimer's disease therapeutics, was developed using the drug repurposing approach and a protease activity discovered by the company's co-founder, Professor Vivian Hook at the University of California, San Diego. Watch Presentation...

 

September 8, 2011:

Researchers from University of California, San Diego, ALSP Inc., and the Medical University of South Carolina published in the Biochimica et Biophysica Acta data discovering biological roles of Cathepsin L and B which indicate their significance in human health and disease. Read More...

 

May 25, 2011: Researchers from ALSP Inc., the Medical University of South Carolina and the University of California, San Diego, published in the Journal of Alzheimer's Disease data showing that cysteine protease inhibitor E64d is efficacious in Alzheimer's disease animal models when orally administered. Read More...

 

February 6-8, 2011: Dr. James Hogan, post-doctoral fellow at ALSP Inc., received "ADDF Young Investigator Scholarship". The award was presented at the "5th Drug Discovery for Neurodegeneration" meeting in San Diego February 6-8, 2011. Read More...

 

December 1-4, 2010: Dr. Greg Hook of ALSP Inc. and his colleagues Dr. Vivian Hook of UCSD and Dr. Mark Kindy of the Medical University of South Carolina, presented three papers at Cold Spring Harbor Laboratory 2010 Meeting on NEURO- DEGENERATIVE DISEASES: BIOLOGY & THERAPEUTICS Read More...

 

November 13-17, 2010: Dr. Greg Hook of ALSP Inc. and his colleagues Dr. Vivian Hook of UCSD and Dr. Mark Kindy of the Medical University of South Carolina, presented three papers at NEUROSCIENCE 2010 in San Diego

Read More...

 

November 9, 2010: ALSP Inc. receives funding from federal program Therapeutic Discovery Project

Read More...

 

May 24, 2010: Alzheimer's Drug Discovery Foundation, ADDF, funds ALSP Inc. to move novel therapeutic towards clinic

Read More...

 

To read more about previous ALSP Inc. news and events, please click here.

                                               

Focusing on a Future without Alzheimer's Disease

 

 

ALSP Inc. (American Life Science Pharmaceuticals, Inc.), is a privately held

company based in San Diego, California, developing small molecule drugs for treating neurodegenerative diseases, initially focused on Alzheimer's disease. Our approach is to identify key enzymes in the brain, called neuroproteases that produce biologically active peptides that are thought to cause the disease. We then use those enzymes as targets for screening compounds that inhibit the neuroproteases and thereby reduce production of the harmful peptides to treat the disease.

 

By using this innovative process, we have identified a family of drugs that is highly effective at reversing the symptoms of Alzheimer's in animal models of the disease. We are advancing our lead compound into clinical trials and continuing our search for additional drugs to treat Alzheimer’s and other devastating neurodegenerative diseases.

American Life Science Pharmaceuticals welcomes inquiries from potential investors.